InStent gets conditional investigational device exemption (IDE) for stent trial
This article was originally published in Clinica
Executive Summary
InStent has received conditional IDE approval to begin clinical trials of its coronary stent CardioCoil. A non-randomised 70-patient study will be conducted at five centres in the US and one in Israel. The trial could start by the end of the year, if InStent can satisfy the FDA's reservations.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.